Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer

Regeneron Pharmaceuticals

Investors are enamored with high profile stocks and ignoring ones that are solid investments. Here are three biotech stocks to consider.

3 Under-the-Radar Biotech Stocks to Buy After Dull Earnings Reactions

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. for BAVENCIO® (avelumab), the first and only immunotherapy approved as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma. BA

4D pharma Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with BAVENCIO® for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

4D pharma PLC (LON:DDDD) has signed a clinical trial collaboration and supply agreement with Merck KGaA, and Pfizer Inc. As part of the tie-up, 4D pharma will start a clinical trial this year with BAVENCIO, a drug for advanced or metastatic urothelial carcinoma developed by Merck and Pfizer, in combination with UK group's MRx0518. "With this second clinical trial collaboration for MRx0518 with a leading immune checkpoint inhibitor, 4D is able to evaluate MRx0518 in a new combination and earlier treatment setting,” said 4D chief executive Duncan Peyton.

4D pharma PLC inks clinical trial collaboration and supply agreement with Merck KGaA, and Pfizer Inc

Merck CEO Ken Frazier is retiring in June. He leaves a legacy of a focus on research, and a commitment to social justice that he's likely to continue.

Merck CEO says public service is in his future, but not politics, as he plans June retirement

Current CFO Robert Davis will be his replacement.

Merck CEO Kenneth Frazier Stepping Down

Kenneth Frazier, one of only a handful of black executives leading major US companies, will step down as chief executive officer at the end of June and be replaced by Chief Financial Officer Robert Davis, Merck said on Thursday. Frazier, 66, will not be handing over the reins completely, at least for now.

Merck CEO Kenneth Frazier to retire at the end of June

Today Merck (NYSE: MRK) announced that Kenneth C. Frazier, chairman and chief executive officer, will retire as CEO, effective June 30, 2021.

Merck CEO Kenneth C. Frazier Retiring And Robert Davis Named As Successor

The COVID-19 pandemic was one major culprit.

What's Behind Merck's Disappointing Q4 Results?

Merck & Co., Inc. (MRK) CEO Ken Frazier on Q4 2020 Results - Earnings Call Transcript

Merck & Co. Inc. (NYSE: MRK) published its earnings report for the fiscal fourth quarter on Thursday that came in weaker than what analysts had anticipated. The company, however, gave upbeat guidance for the full financial year on Thursday.

Merck & Co swings to £1.53 billion of net loss in the fourth quarter

Merck (MRK) misses Q4 estimates for earnings and sales. CEO Kenneth C.

Merck (MRK) Q4 Earnings & Sales Miss, CEO Frazier Steps Down

Merck stock dipped Thursday on a disappointing quarter that lagged forecasts as Chief Executive Kenneth Frazier prepares to step down. Chief Financial Officer Robert Davis will succeed him.

Merck Topples On 'Disappointing Quarter' As CEO Kenneth Frazier Steps Down

Frazier will be succeeded by current CFO Robert Davis.

Merck's Ken Frazier, One Of Four Black Fortune 500 CEOs, Will Retire In June

Merck & Co. Inc (NYSE: MRK) reported a fourth-quarter profit of $1.32 per share, which missed the analyst consensus estimate of $1.38. Sales grew 5% to $12.51 billion, marginally missing the consensus estimate of $12.68 billion.

Merck Posts Mixed Q4 Earnings; Kenneth Frazier To Step Down As CEO

Merck's current executive vice president, Robert Davis, will succeed him.

Merck Announces New CEO, But Reports Earnings Miss

Merck CEO Kenneth Frazier, who is currently one of the few Black CEOs of a Fortune 500 company, is retiring in June, ending a nearly 30-year run with the company.

Ken Frazier, one of the only Black Fortune 500 CEOs, is retiring

The Merck CEO oversaw the development of important cancer immunotherapy drugs and an HPV vaccine during his tenure. First, it was Jeff Bezos announcing he's stepping down as chief executive officer of Amazon, now it's Kenneth Frazier—a busy week for CEO exits.

Merck CEO Kenneth Frazier announces retirement

Merck & Co said on Thursday Kenneth Frazier, one of only a handful of Black CEOs leading major U.S. companies, would step down as chief executive officer at the end of June to be replaced by Chief Financial Officer Robert Davis.

U.S. drugmaker Merck's Kenneth Frazier to step down as CEO

Merck & Co. Inc. said Thursday that Chief Executive Kenneth Frazier will retire, effective June 30, after 10 years in the role, and 29 years with the company. The drug maker said it elected Chief Financial Officer Robert Davis as the next CEO.

Merck CEO Kenneth Frazier to retire after 10 years in the role

Shares of Merck & Co. Inc. slipped 0.2% in premarket trading Thursday, after the drug maker reported a fourth-quarter profit that missed expectations, but revenue that beat and provided and upbeat full-year outlook. The company swung to a net loss of $2.09 billion, or 83 cents a share, from net income of $2.36 billion, or 92 cents a share, in the year-ago period.

Merck misses profit expectations but beats on revenue, provides upbeat outlook

Merck CEO Ken Frazier will retire effective June 30, the company announced.

Merck says Kenneth Frazier to retire as CEO effective June 30

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results

Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Kenneth C. Frazier to Retire as Merck CEO; Board Elects Robert M. Davis as Successor; Frazier to Continue as Executive Chairman

Kenneth C. Frazier to Retire as Merck CEO; Board Elects Robert M. Davis as Successor; Frazier to Continue as Executive Chairman

Merck is scheduled to report its Q4 2020 results on Thursday, February 4. We expect the company to likely post revenue slightly below and earnings in-line with the consensus estimates, partly due to lower expected sales of vaccines, such as Gardasil and Proquad.

Merck Q4 Earnings Preview: Keytruda And Gardasil In Focus

eXp World Holdings Inc

Right now, most investors are oblivious to OptimizeRX and eXp World Holdings. Here's why you should know their names.

News for Merck Stock (MRK)